$ (0.29)$ 0.10Adjustments to net (loss) income (as detailed below)
0.660.24Non-GAAP adjusted earnings per share- Diluted
(2)NET (LOSS) INCOMEGAAP net (loss) income
$ (77,767)$ 27,569Adjustments:Contingent revenue from Novartis collaboration
11,606-Amortization of intangible assets
40,39911,316Non-cash interest expense relating to convertible notes
38,513367Restructuring and divestiture costs
16,697(71)Fair value write-up of acquired inventory sold
19,918-Impairment of goodwill
5,826-In-process research and development
4,500-Fair value adjustment for depreciation expense
2,503-Other (benefits) charges
(425)320Income tax effect of reconciling items
(3)Non-GAAP adjusted net income
$ 98,334$ 88,786EBITDANon-GAAP adjusted net income
$ 98,334$ 88,786Interest expense, net, not adjusted above
39,7669,887Provision for income taxes
50,65743,692Depreciation expense, not adjusted above
$ 209,998$ 160,273EXPLANATORY NOTES:(1) To reflect a fair value adjustment recorded in purchase accounting relating to contingent revenue earned and received under the Novartis collaboration post acquisition which was eliminated under purchase accounting.
(2) Non-GAAP adjusted earnings per share was calculated based on 268,106 and 264,878 weighted average diluted shares outstanding for the three months ended September 29, 2012 and September 24, 2011, respectively.
(3) To reflect an annual effective tax rate of 34.0% and 33.2% on a non-GAAP basis for the three months ended September 29, 2012 and September 24, 2011, respective
|SOURCE Hologic, Inc.|
Copyright©2012 PR Newswire.
All rights reserved